Vivos Therapeutics (VVOS)
NASDAQ:VVOS
Want to see VVOS full AI Analyst Report?
VVOS Stock Chart & Stats
$2.22
-$0.06(-1.47%)
At close: 4:00 PM EST
$2.22
-$0.06(-1.47%)
Day’s Range― - ―
52-Week Range$0.55 - $7.95
Previous CloseN/A
Volume144.69K
Average Volume (3M)421.86K
Market Cap
$9.73M
Enterprise Value$14.28M
Total Cash (Recent Filing)$2.11M
Total Debt (Recent Filing)$12.27M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Aug 19, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding13,894,600
10 Day Avg. Volume324,525
30 Day Avg. Volume421,860
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-14.00
Price to Sales (P/S)1.20
P/FCF Ratio-1.18
Enterprise Value/Market Cap1.47
Enterprise Value/Revenue0.73
Enterprise Value/Gross Profit1.18
Enterprise Value/Ebitda-0.68
Forecast
1Y Price Target
$2.42Price Target Upside8.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.15
Revenue Forecast (FY)$23.27M
Bulls Say, Bears Say
Bulls Say
Commercial Partnerships And ScalingContractual partnerships and a roll-up strategy with sleep specialty providers create scalable distribution channels and potential recurring revenue through shared-revenue arrangements with centers.
M&A And Revenue DiversificationAcquisition of The Sleep Center of Nevada enables capture of diagnostic and consulting revenues, creating higher-margin service streams that complement device sales.
Regulatory ApprovalFDA clearance of the DNA appliance for moderate-to-severe obstructive sleep apnea and pediatric use broadens clinical indications and supports wider clinician adoption and reimbursement discussions.
Bears Say
Liquidity And FinancingLimited cash on hand combined with a quarterly cash burn that exceeds available cash requires additional financing, raising dilution and execution risk if capital access tightens.
Operating ExpensesSignificant operating-cost increases tied to SCN integration are pressuring margins and could slow progress toward sustained profitability.
Profitability OutlookClassification of some costs as transitional still leaves uncertainty about when integration expenses will subside, complicating visibility into near-term profitability improvement.
Vivos Therapeutics News
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $0.55 and its highest was $7.95 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Vivos Therapeutics’s market cap is $9.73M.
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 80 days.
How were Vivos Therapeutics’s earnings last quarter?
Currently, no data Available
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Undervalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -0.33.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 13,894,600 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
VVOS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted very strong top-line momentum—70% year-over-year revenue growth, 34% sequential growth, a 10 percentage-point gross margin improvement and rapidly rising patient volumes and KPIs driven by the SCN acquisition and provider productivity gains. However, these operational gains were offset by substantial increases in G&A and cash burn, a low cash balance (~$2.1M), increased discounts reducing product revenue, and an explicit need for additional financing and debt restructuring. Management presented multiple high-margin initiatives (pediatrics, insomnia services, medical affiliations) that could materially improve profitability, but near-term execution and capital availability remain material risks.View all VVOS earnings summariesVVOS Stock 12 Month Forecast
Average Price Target
$2.42
▲(8.86% Upside)
Technical Analysis
Iridex
―
Co-Diagnostics
―
Adagio Medical Holdings
―
Envoy Medical
―
Nexalin Technology, Inc.
―
Ownership Overview
9.74% Insiders
2.26% Mutual Funds
8.96% Other Institutional Investors
77.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---